PersonGen BioTherapeutics (Suzhou) Co., Ltd.
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Explore linked clinical trials.13 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma | CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma | Recruiting | Phase 2 | 2026-07-06 | NCT07188610 | |
| Single-arm, Open-label, Dose-escalating Phase I Clinical Study of PA3-17 Injection in Children and Adolescents With Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma | CD7+ T-ALL/LBL | Not yet recruiting | Phase 1 | 2026-06-03 | NCT07623681 | |
| Clinical Study of UTAA07 Injection in the Treatment of Hematologic and Lymphatic Systemic Malignancies | Hematolymphoid Malignancies | Recruiting | Early phase 1 | 2026-01-14 | NCT07338604 | |
| Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Early phase 1 | 2025-12-31 | NCT07312630 | |
| Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm, non-Hodgkin lymphoma | Recruiting | Phase 1 | 2025-12-16 | NCT07284927 | |
| Clinical Study on the Treatment of Refractory Rheumatoid Arthritis With UTAA91 Injection | Skin and Connective Tissue Diseases, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, immune system disorder, musculoskeletal system disorder, rheumatic disorder, rheumatoid arthritis | Not yet recruiting | Early phase 1 | 2025-05-21 | NCT06982547 | |
| Clinical Study on the Treatment of Systemic Sclerosis With UTAA91 Injection. | Skin and Connective Tissue Diseases, connective tissue disorder, skin disorder, systemic sclerosis | Not yet recruiting | Early phase 1 | 2025-05-21 | NCT06982534 | |
| UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies. | CD19-positive Relapsed or Refractory B-cell Malignancies | Recruiting | Early phase 1 | 2025-05-16 | NCT06092047 | |
| Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases | Skin and Connective Tissue Diseases, acquired idiopathic inflammatory myopathy, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, immune system disorder, muscle tissue disorder, musculoskeletal system disorder, myositis disease, nervous system disorder, neuromuscular disease, rheumatic disorder, rheumatoid arthritis, skin disorder, systemic lupus erythematosus, systemic sclerosis | Not yet recruiting | Early phase 1 | 2025-05-14 | NCT06970951 | |
| Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune Diseases | Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria | Not yet recruiting | Not applicable | 2025-03-12 | NCT06871644 | |
| UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Not applicable | 2024-02-26 | NCT06279026 | |
| TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma | B7-H3-positive Relapsed/ Refractory Neuroblastoma | Recruiting | Phase 1 | 2023-02-27 | NCT05562024 | |
| Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 1 | 2022-07-06 | NCT05445011 |